search
Back to results

Exercise With Individual Dosage Against the Best Current Practice in Lower Limb Tendinopathy (MaLaGa Trial) (MaLaGa)

Primary Purpose

Tendinopathy

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Best current practice exercise programme
Experimental exercise programme
Sponsored by
University of Malaga
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tendinopathy focused on measuring tendinopathy, exercise, dosage, physiotherapy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. People between 18 and 65 years with a clinical diagnosis of mid-portion Achilles, patellar, or gluteal tendinopathy;
  2. Pain duration for at least one month.

Exclusion Criteria:

  1. Corticosteroid injection in the studied tendon in the last 12 months;
  2. Other injuries in the affected lower limb in the last 12 months;
  3. Previous surgery for musculoskeletal causes of the affected lower limb in the last 12 months;
  4. Tendinous rupture history in the affected lower limb;
  5. Systemic diseases such as rheumatic arthritis or diabetes mellitus.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Best current practice exercise programme

    Experimental exercise programme

    Arm Description

    Therapeutic physical exercise, best current practice: Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group). Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group). Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).

    Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages): Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly

    Outcomes

    Primary Outcome Measures

    Victorian Institute of Sport Assessment (VISA) questionnaire POST
    Visa-A for Achilles tendon, Visa-P for Patellar tendon, Visa-G for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).

    Secondary Outcome Measures

    Victorian Institute of Sport Assessment (VISA) questionnaire PRE
    Visa-A model for Achilles tendon, Visa-P model for Patellar tendon, Visa-G model for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Victorian Institute of Sport Assessment (VISA) questionnaire SHOR TERM
    Visa-A for Achilles tendon, Visa-P for Patellar tendon, Visa-G for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Victorian Institute of Sport Assessment (VISA) questionnaire Follow-up
    Visa-A for Achilles tendon, Visa-P for Patellar tendon, Visa-G for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Central Sensitization Inventory (CSI) PRE
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Central Sensitization Inventory (CSI) SHORT TERM
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Central Sensitization Inventory (CSI) POST
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Central Sensitization Inventory (CSI) FOLLOW-UP
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) PRE
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) SHORT TERM
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) POST
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) FOLLOW-UP
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Fear Avoidance Components Scale (FACS) PRE
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Fear Avoidance Components Scale (FACS) SHORT TERM
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Fear Avoidance Components Scale (FACS) POST
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Fear Avoidance Components Scale (FACS) FOLLOW-UP
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    European Quality of Life-5 Dimensions (EQ-5D) PRE
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    European Quality of Life-5 Dimensions (EQ-5D) SHORT TERM
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    European Quality of Life-5 Dimensions (EQ-5D) POST
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    European Quality of Life-5 Dimensions (EQ-5D) FOLLOW-UP
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    Lower Limb Functional Index (LLFI) PRE
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Lower Limb Functional Index (LLFI) POST
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Lower Limb Functional Index (LLFI) SHORT TERM
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Lower Limb Functional Index (LLFI) FOLLOW-UP
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Lower limb Strength PRE
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Lower limb Strength SHORT TERM
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Lower limb Strength POST
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Lower limb Strength FOLLOW-UP
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Muscular Thickness PRE
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Muscular Thickness SHORT TERM
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Muscular Thickness POST
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Muscular Thickness FOLLOW-UP
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Pressure Pain Threshold PRE
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Pressure Pain Threshold SHORT TERM
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Pressure Pain Threshold POST
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Pressure Pain Threshold FOLLOW-UP
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Pain at rest measured with Visual Analogue Scale (VAS) PRE
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain at rest measured with Visual Analogue Scale (VAS) SHORT TERM
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain at rest measured with Visual Analogue Scale (VAS) POST
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain at rest measured with Visual Analogue Scale (VAS) FOLLOW UP
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain during activity (running) measured with Visual Analogue Scale (VAS) PRE
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain during activity (running) measured with Visual Analogue Scale (VAS) SHORT-TERM
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain during activity (running) measured with Visual Analogue Scale (VAS) POST
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Pain during activity (running) measured with Visual Analogue Scale (VAS) FOLLOW UP
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Treatment satisfaction PRE
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Treatment satisfaction SHORT-TERM
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Treatment satisfaction POST
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Treatment satisfaction FOLLOW UP
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Lower limb Strength measured with hand-held dinamometer PRE
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Lower limb Strength measured with hand-held dinamometer POST
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Lower limb Strength measured with hand-held dinamometer SHORT TERM
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Lower limb Strength measured with hand-held dinamometer FOLLOW UP
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    HDEMG profile with Non Invasive Surface High-Density Electromyography (HDEMG) PRE
    Non invasive surface HDEMG during maximal isometric voluntary contraction performed in a leg press machine. Surface HDEMG is recorded during 20 seconds. Data obtained is analysed to extract the mean discharge rate of the motor units (in fires per second) and the recruitment and derecruitment threshold (in Nw). This variable will only be assessed in a randomly selected subgroup of each arm.
    HDEMG profile with Non Invasive Surface High-Density Electromyography (HDEMG) POST
    Non invasive surface HDEMG during maximal isometric voluntary contraction performed in a leg press machine. Surface HDEMG is recorded during 20 seconds. Data obtained is analysed to extract the mean discharge rate of the motor units (in fires per second) and the recruitment and derecruitment threshold (in Nw). This variable will only be assessed in a randomly selected subgroup of each arm.
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.

    Full Information

    First Posted
    February 11, 2019
    Last Updated
    May 24, 2021
    Sponsor
    University of Malaga
    Collaborators
    Ministry of Science, Innovation and Universities, Spain
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03853122
    Brief Title
    Exercise With Individual Dosage Against the Best Current Practice in Lower Limb Tendinopathy (MaLaGa Trial)
    Acronym
    MaLaGa
    Official Title
    Effect of a Common Exercise Programme With an Individualized Progression Criterion Based on the Measurement of Neuromuscular Capacity Versus Eccentric Training for Lower Limb Tendinopathies (MaLaGa Trial): Randomised Clinical Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    June 1, 2021 (Anticipated)
    Primary Completion Date
    July 2022 (Anticipated)
    Study Completion Date
    December 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Malaga
    Collaborators
    Ministry of Science, Innovation and Universities, Spain

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study compares the effect of a therapeutic physical exercise programme based on an individualized control of the exercise dose by monitoring the force-speed curves against the current best practice in the treatment of tendinopathies of the lower limb. Half of the participants will receive the experimental intervention, while the other half will receive the best current practice.
    Detailed Description
    The current best practice is based on a progressive strength training sustained in the continuous model of tendinopathy proposed by Cook and Purdam (Cook & Purdam, 2009), showing in the literature this methodology more effective than the wait and see approach or that the use of corticosteroid injections, accentuating the differences in long-term follow-up evaluations (Mellor et al., 2018). However, the current system lacks an objectification methodology for the severity of the pathology and objective criteria for the progression of the load, usually based on subjective feelings of discomfort or pre-established intensities. Therefore, the investigators hypothesize that the development and introduction of a methodology for the quantification and progression of the loads, with an individual control and management of the exercise dose, as well as the execution of specific exercises for each one of them, could improve the clinica and functional results. Moreover, achieving neuromuscular adaptations based on the characteristics of the neuromuscular system, could improve the times and results of the intervention, as well as the rate of treatment failures, in the tendinopathies of the lower limbs.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Tendinopathy
    Keywords
    tendinopathy, exercise, dosage, physiotherapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    Randomized controlled trial, with two parallel groups (control and intervention)
    Masking
    Outcomes Assessor
    Masking Description
    Assessors are not aware of the allocation group of the participants
    Allocation
    Randomized
    Enrollment
    104 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Best current practice exercise programme
    Arm Type
    Active Comparator
    Arm Description
    Therapeutic physical exercise, best current practice: Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group). Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group). Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).
    Arm Title
    Experimental exercise programme
    Arm Type
    Experimental
    Arm Description
    Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages): Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly
    Intervention Type
    Other
    Intervention Name(s)
    Best current practice exercise programme
    Other Intervention Name(s)
    Alfredson protocol, LEAP protocol
    Intervention Description
    Therapeutic Physical Exercise programme based on the protocol of Afredson (for Achilles and patellar tendinopathies) and LEAP (for gluteal tendinopathy). Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetitions of two eccentric exercises Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: 3 sets of 15 repetions of one eccentric exercise Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL: an exercise programme divided into stages with progression in different exercises, volumes and loads
    Intervention Type
    Other
    Intervention Name(s)
    Experimental exercise programme
    Other Intervention Name(s)
    MaLaGa protocol
    Intervention Description
    Therapeutic Physical Exercise programme structured in five stages oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
    Primary Outcome Measure Information:
    Title
    Victorian Institute of Sport Assessment (VISA) questionnaire POST
    Description
    Visa-A for Achilles tendon, Visa-P for Patellar tendon, Visa-G for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Secondary Outcome Measure Information:
    Title
    Victorian Institute of Sport Assessment (VISA) questionnaire PRE
    Description
    Visa-A model for Achilles tendon, Visa-P model for Patellar tendon, Visa-G model for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Victorian Institute of Sport Assessment (VISA) questionnaire SHOR TERM
    Description
    Visa-A for Achilles tendon, Visa-P for Patellar tendon, Visa-G for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Victorian Institute of Sport Assessment (VISA) questionnaire Follow-up
    Description
    Visa-A for Achilles tendon, Visa-P for Patellar tendon, Visa-G for Gluteal tendon: functional mobility, life participation, and pain. Assessed from 0 (worst value) to 100 (best value).
    Time Frame
    52 weeks after the start of the intervention
    Title
    Central Sensitization Inventory (CSI) PRE
    Description
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Central Sensitization Inventory (CSI) SHORT TERM
    Description
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Central Sensitization Inventory (CSI) POST
    Description
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Central Sensitization Inventory (CSI) FOLLOW-UP
    Description
    Questionnaire to help identify patients with Central Sensitivity Syndromes. Range 0-100. Five severity levels developed to help aid in the clinical interpretation of the CSI (subclinical = 0-29; mild = 30-39; moderate = 40-49; severe = 50-59; and extreme = 60-100)
    Time Frame
    52 weeks after start of the intervention
    Title
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) PRE
    Description
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) SHORT TERM
    Description
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) POST
    Description
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) FOLLOW-UP
    Description
    OMPSQ is a self-administered pain screening questionnaire applied to identify patients with acute or subacute musculoskeletal pain who are at risk of delayed recovery. A higher score indicates a higher disability. The maximum score is 210 points; a score of < 105 points indicates a low disability, that between 105 and 130 points indicates a moderate disability and that > 130 points indicates a high disability
    Time Frame
    52 weeks after start of the intervention
    Title
    Fear Avoidance Components Scale (FACS) PRE
    Description
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Fear Avoidance Components Scale (FACS) SHORT TERM
    Description
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Fear Avoidance Components Scale (FACS) POST
    Description
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Fear Avoidance Components Scale (FACS) FOLLOW-UP
    Description
    The FACS scale comprehensively assesses the presence of fear avoidance beliefs and attitudes in people with painful medical conditions. The FACS instructions ask participants to reflect on past painful experiences, and to indicate the degree to which these experiences influence on their activity. There are 20 thoughts or feelings related to avoidance, on 6-point scales with the end points (0) completely disagree and (5) completely agree. The FACS yields a total score between 0, best score, and 100, worst score.
    Time Frame
    52 weeks after start of the intervention
    Title
    European Quality of Life-5 Dimensions (EQ-5D) PRE
    Description
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    European Quality of Life-5 Dimensions (EQ-5D) SHORT TERM
    Description
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    European Quality of Life-5 Dimensions (EQ-5D) POST
    Description
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    European Quality of Life-5 Dimensions (EQ-5D) FOLLOW-UP
    Description
    EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. Each dimension is rated in 5 levels from "I have no problem with..." to "I am unable to..."
    Time Frame
    52 weeks after start of the intervention
    Title
    Lower Limb Functional Index (LLFI) PRE
    Description
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Lower Limb Functional Index (LLFI) POST
    Description
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Lower Limb Functional Index (LLFI) SHORT TERM
    Description
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Lower Limb Functional Index (LLFI) FOLLOW-UP
    Description
    The LLFI is an index designed for assessing the functional capacity of the lower limbs with a combination of constructs that includes body functions, body structures, activities and participation, and environmental factors. The LLFI has 25 phrases as items and participants have to select which ones they identify with. The final score is calculated with the following formula: 100 - (number of sentences chosen x 4). The LLFI yields a total score (between 100, best score, and 0, worst score).
    Time Frame
    52 weeks after start of the intervention
    Title
    Lower limb Strength PRE
    Description
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Lower limb Strength SHORT TERM
    Description
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Lower limb Strength POST
    Description
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Lower limb Strength FOLLOW-UP
    Description
    Assessment of the isometric strength in the leg press machine using a s-beam load cell
    Time Frame
    52 weeks after start of the intervention
    Title
    Muscular Thickness PRE
    Description
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Muscular Thickness SHORT TERM
    Description
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Muscular Thickness POST
    Description
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Muscular Thickness FOLLOW-UP
    Description
    Measurement of the muscular thickness (in cm) by Ultrasonography
    Time Frame
    52 weeks after start of the intervention
    Title
    Pressure Pain Threshold PRE
    Description
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Pressure Pain Threshold SHORT TERM
    Description
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Pressure Pain Threshold POST
    Description
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Pressure Pain Threshold FOLLOW-UP
    Description
    Measurement of the Pressure Pain Threshold of tendon with a hand-held algometer. The tester is placed perpendicular to the skin over the test area, increasing the pressure 30kPa/s. Participants are instructed to indicate when the sensation change from comfortable pressure to slightly unpleasant pain. Test is repeated three times with one minute of rest between repetitions. The mean value is used for the analysis.
    Time Frame
    52 weeks after start of the intervention
    Title
    Pain at rest measured with Visual Analogue Scale (VAS) PRE
    Description
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Pain at rest measured with Visual Analogue Scale (VAS) SHORT TERM
    Description
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Pain at rest measured with Visual Analogue Scale (VAS) POST
    Description
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Pain at rest measured with Visual Analogue Scale (VAS) FOLLOW UP
    Description
    Measurement of the Pain at rest with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    52 weeks after start of the intervention
    Title
    Pain during activity (running) measured with Visual Analogue Scale (VAS) PRE
    Description
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Pain during activity (running) measured with Visual Analogue Scale (VAS) SHORT-TERM
    Description
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Pain during activity (running) measured with Visual Analogue Scale (VAS) POST
    Description
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Pain during activity (running) measured with Visual Analogue Scale (VAS) FOLLOW UP
    Description
    Measurement of the Pain during activity (running) with a 100 mm VAS scale, 0 being no pain and 100 being the worst imaginable pain
    Time Frame
    52 weeks after start of the intervention
    Title
    Treatment satisfaction PRE
    Description
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Treatment satisfaction SHORT-TERM
    Description
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Treatment satisfaction POST
    Description
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Treatment satisfaction FOLLOW UP
    Description
    Treatment satisfaction assessed using a visual analog scale, from 0 to 100mm, with 0 being "not at all satisfied" and 10 being "extremely satisfied".
    Time Frame
    52 weeks after start of the intervention
    Title
    Lower limb Strength measured with hand-held dinamometer PRE
    Description
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Lower limb Strength measured with hand-held dinamometer POST
    Description
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Lower limb Strength measured with hand-held dinamometer SHORT TERM
    Description
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Lower limb Strength measured with hand-held dinamometer FOLLOW UP
    Description
    Lower limb Strength measured with hand-held dinamometer (ankle plantarflexion for Achilles tendinopathy, knee extension for patellar tendinopathy, and hip abduction for gluteal tendinopathy). Two repetitions are performed and the mean value is used for the analysis.
    Time Frame
    52 weeks after start of the intervention
    Title
    HDEMG profile with Non Invasive Surface High-Density Electromyography (HDEMG) PRE
    Description
    Non invasive surface HDEMG during maximal isometric voluntary contraction performed in a leg press machine. Surface HDEMG is recorded during 20 seconds. Data obtained is analysed to extract the mean discharge rate of the motor units (in fires per second) and the recruitment and derecruitment threshold (in Nw). This variable will only be assessed in a randomly selected subgroup of each arm.
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    HDEMG profile with Non Invasive Surface High-Density Electromyography (HDEMG) POST
    Description
    Non invasive surface HDEMG during maximal isometric voluntary contraction performed in a leg press machine. Surface HDEMG is recorded during 20 seconds. Data obtained is analysed to extract the mean discharge rate of the motor units (in fires per second) and the recruitment and derecruitment threshold (in Nw). This variable will only be assessed in a randomly selected subgroup of each arm.
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Description
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Time Frame
    Baseline, 1 week before start of the intervention
    Title
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Description
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Time Frame
    Short term, 7 weeks after start of the intervention
    Title
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Description
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Time Frame
    Post, 14 weeks after start of the intervention (when intervention is finished)
    Title
    Amount of physical activity with International Physical Activity Questionnaire Short Form (IPAQ-SF)
    Description
    Amount of physical activity of the patients through seven questions about the physical activity performed the previous seven days. Physical activity can be interpreted as a numerical value (reported as median MET-minutes) and as low, moderate, or high activity levels.
    Time Frame
    52 weeks after start of the intervention

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: People between 18 and 65 years with a clinical diagnosis of mid-portion Achilles, patellar, or gluteal tendinopathy; Pain duration for at least one month. Exclusion Criteria: Corticosteroid injection in the studied tendon in the last 12 months; Other injuries in the affected lower limb in the last 12 months; Previous surgery for musculoskeletal causes of the affected lower limb in the last 12 months; Tendinous rupture history in the affected lower limb; Systemic diseases such as rheumatic arthritis or diabetes mellitus.

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    34404699
    Citation
    Escriche-Escuder A, Cuesta-Vargas AI, Casana J. Effect of a common exercise programme with an individualised progression criterion based on the measurement of neuromuscular capacity versus current best practice for lower limb tendinopathies (MaLaGa trial): a protocol for a randomised clinical trial. BMJ Open. 2021 Aug 17;11(8):e046729. doi: 10.1136/bmjopen-2020-046729.
    Results Reference
    derived

    Learn more about this trial

    Exercise With Individual Dosage Against the Best Current Practice in Lower Limb Tendinopathy (MaLaGa Trial)

    We'll reach out to this number within 24 hrs